Vaccine-induced seropositivity/seroreactivity (VISP/R) on common HIV screening assays after vaccination with investigational adenovirus vector-based mosaic HIV regimens in clinical trials.

Saved in:
Bibliographic Details
Title: Vaccine-induced seropositivity/seroreactivity (VISP/R) on common HIV screening assays after vaccination with investigational adenovirus vector-based mosaic HIV regimens in clinical trials.
Authors: Callewaert K; Johnson & Johnson, Beerse, Belgium. Electronic address: kcallewa@its.jnj.com., Lavreys L; Johnson & Johnson, Beerse, Belgium. Electronic address: llavrey1@its.jnj.com., Willems W; Johnson & Johnson, Beerse, Belgium. Electronic address: wwillem7@its.jnj.com., van Rosmalen MGM; Johnson & Johnson, Leiden, The Netherlands. Electronic address: mariska.vanrosmalen@gmail.com., Salzgeber Y; Johnson & Johnson, Bern, Switzerland. Electronic address: ysalzgeb@its.jnj.com., Pau MG; Johnson & Johnson, Leiden, The Netherlands. Electronic address: mpau@its.jnj.com., Oriol Mathieu V; Johnson & Johnson, Leiden, The Netherlands. Electronic address: voriolm@its.jnj.com., Hartnett J; Johnson & Johnson, Titusville, USA. Electronic address: jhartne1@its.jnj.com., Vingerhoets J; Johnson & Johnson, Beerse, Belgium. Electronic address: jvingerh@its.jnj.com.
Source: Vaccine [Vaccine] 2026 Apr 19; Vol. 79, pp. 128500. Date of Electronic Publication: 2026 Apr 02.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2026.128500